As of March 2025, the U.S. stock market has been grappling with volatility, highlighted by recent declines following the announcement of new tariffs on automobile imports. Despite these broader market challenges, penny stocks remain an intriguing investment avenue for those seeking opportunities in smaller or newer companies. While often seen as a relic from past eras, penny stocks can offer significant growth potential when backed by strong financial health and sound fundamentals.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Safe Bulkers (NYSE:SB) | $3.76 | $392.12M | ✅ 3 ⚠️ 3 View Analysis > |
| Tuya (NYSE:TUYA) | $3.43 | $1.98B | ✅ 3 ⚠️ 3 View Analysis > |
| Cango (NYSE:CANG) | $4.01 | $411.2M | ✅ 4 ⚠️ 1 View Analysis > |
| Sensus Healthcare (NasdaqCM:SRTS) | $4.69 | $76.54M | ✅ 5 ⚠️ 3 View Analysis > |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ✅ 1 ⚠️ 5 View Analysis > |
| TETRA Technologies (NYSE:TTI) | $3.75 | $467.35M | ✅ 5 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.55 | $76.44M | ✅ 3 ⚠️ 1 View Analysis > |
| BAB (OTCPK:BABB) | $0.83 | $5.75M | ✅ 2 ⚠️ 3 View Analysis > |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $153.34M | ✅ 3 ⚠️ 1 View Analysis > |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.7966 | $76.45M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 772 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
OmniAb (NasdaqGM:OABI)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to aid in the discovery of therapeutics across the United States, Europe, Japan, China, and Canada; it has a market cap of $296.79 million.
Operations: The company's revenue segment is derived from Research Services, amounting to $26.39 million.
Market Cap: $296.79M
OmniAb, Inc., a biotechnology company with a market cap of US$296.79 million, has shown volatility typical of penny stocks. Despite being debt-free and having short-term assets of US$68.1 million that exceed liabilities, OmniAb remains unprofitable with increasing losses over the past five years. Recent earnings reported a net loss for 2024 at US$62.03 million on revenues of US$26.39 million, down from the previous year. The company's revenue is forecast to grow by 27% annually but profitability isn't expected in the near term. Strategic alliances like the one with Chiome Bioscience aim to enhance technology synergies and potential future profitability without immediate financial impact.
- Unlock comprehensive insights into our analysis of OmniAb stock in this financial health report.
- Assess OmniAb's future earnings estimates with our detailed growth reports.
Zhihu (NYSE:ZH)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Zhihu Inc. is an online content community platform operating in the People’s Republic of China, with a market cap of approximately $396.83 million.
Operations: The company generates revenue primarily through its advertising segment, which amounted to CN¥3.60 billion.
Market Cap: $396.83M
Zhihu Inc., with a market cap of approximately $396.83 million, remains unprofitable but has shown improvement by reducing its net loss from CN¥843.64 million to CN¥171.8 million in 2024. The company's revenue decreased to CN¥3.60 billion from the previous year, yet it achieved a positive net income of CN¥86.27 million in Q4 2024 compared to a loss the prior year, indicating potential recovery momentum. Zhihu is debt-free and maintains sufficient cash runway for over three years, though its management team lacks extensive experience with an average tenure of just over one year.
- Navigate through the intricacies of Zhihu with our comprehensive balance sheet health report here.
- Review our growth performance report to gain insights into Zhihu's future.
DiDi Global (OTCPK:DIDI.Y)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: DiDi Global Inc. operates a mobility technology platform offering various services in China, Brazil, Mexico, and internationally, with a market cap of approximately $24.16 billion.
Operations: The company's revenue is primarily derived from China Mobility, which generated CN¥183.21 billion, followed by International operations at CN¥10.26 billion and Other Initiatives contributing CN¥9.84 billion.
Market Cap: $24.16B
DiDi Global Inc., with a market cap of approximately $24.16 billion, has transitioned to profitability, showcasing strong financial health. The company trades at a substantial discount to its estimated fair value and offers good relative value compared to peers. Its debt is well-managed, supported by operating cash flow, and short-term assets comfortably cover liabilities. Despite a low return on equity at 8%, earnings are predicted to grow significantly by 33.16% annually. However, the board's inexperience may pose governance challenges. Recent participation in industry conferences highlights ongoing engagement with the investment community.
- Click here and access our complete financial health analysis report to understand the dynamics of DiDi Global.
- Gain insights into DiDi Global's future direction by reviewing our growth report.
Key Takeaways
- Discover the full array of 772 US Penny Stocks right here.
- Contemplating Other Strategies? Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Zhihu might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com